Loading clinical trials...
Loading clinical trials...
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer
Conditions
Interventions
Domvanalimab
Quemliclustat
+3 more
Locations
51
United States
University of Alabama at Birmingham (UAB)
Birmingham, Alabama, United States
University of California San Diego (UCSD)
La Jolla, California, United States
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, Florida, United States
Hematology Oncology Associates Of The Treasure Coast
Port Saint Lucie, Florida, United States
Florida Cancer Specialists (Administration and Drug Shipment)
The Villages, Florida, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
Start Date
February 21, 2023
Primary Completion Date
December 1, 2027
Completion Date
December 1, 2027
Last Updated
October 2, 2025
NCT06731413
NCT07356544
NCT06956001
NCT06706076
NCT07371663
NCT07222566
Lead Sponsor
Gilead Sciences
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions